02/02/23 4:30 PMNasdaq : SESN acquisitionSesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics MergerSesen Bio, Inc. today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc.. The merger with Carisma delivers substantial and immediate value for Sesen Bio stockholders, which is meaningfully better than the alternative of dissolution and liquidation Expected special one-time cash dividend of...RHEA-AIneutral
01/30/23 8:00 AMNasdaq : SESN Sesen Bio Receives NASDAQ Delisting NoticeSesen Bio, Inc. today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC that, based upon the Company’ s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company’ s common stock is subject to delisting. The receipt of this notice from Nasdaq...RHEA-AIneutral
01/26/23 8:00 AMNasdaq : SESN acquisitionSesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of StockholdersSesen Bio, Inc. today issued the following statement reiterating the Company’ s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates:. In contrast, we believe the Investor Group continues to be opportunistic and single-minded,...RHEA-AIneutral
01/25/23 8:00 AMNasdaq : SESN acquisitionInvestor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger SupportBradley L. Radoff and Michael Torok, who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc., today issued the following open letter to the Boards of Directors of Sesen Bio and Carisma Therapeutics Inc.:. Members of the Sesen Bio and Carisma Boards,. The cash dividend being paid to Sesen Bio stockholders is, in our view, insufficient. The proposed...RHEA-AIneutral
01/19/23 4:28 PMNasdaq : SESN acquisitionSesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma TherapeuticsSesen Bio, Inc. today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’ s pending merger with Carisma Therapeutics Inc., a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies.RHEA-AIneutral
01/05/23 8:00 AMNasdaq : SESN managementacquisitionInvestor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma MergerBradley L. Radoff and Michael Torok, who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc., today issued the following open letter to the Company’ s Board of Directors regarding the proposed merger with Carisma Therapeutics Inc.:. The Investor Group remains adamantly opposed to Sesen Bio’ s proposed merger with Carisma. Last week’ s...RHEA-AIneutral
01/04/23 8:00 AMNasdaq : SESN acquisitionSesen Bio Reiterates Confidence in Pending Merger with Carisma TherapeuticsSesen Bio, Inc. today issued the following statement reiterating the Company’ s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. as the best path forward for stockholders. The Sesen Bio Board of Directors remains confident that the pending merger with Carisma represents the most value maximizing path forward..RHEA-AIneutral
01/03/23 8:00 AMNasdaq : SESN acquisitionInvestor Group Reiterates Intent to Vote AGAINST Sesen Bio’s Value-Destructive Merger with CarismaBradley L. Radoff and Michael Torok, who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc., today reiterated their intent to vote AGAINST the Company’ s proposed merger with Carisma Therapeutics Inc. through the following statement:. “After reviewing the amended merger terms disclosed last week, the Investor Group remains firmly opposed...RHEA-AIneutral
12/29/22 4:33 PMNasdaq : SESN dividendsacquisitionSesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending MergerSesen Bio, Inc. and Carisma Therapeutics Inc., a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced an amendment to their previously announced merger agreement dated September 20, 2022. Under the terms of the amended merger agreement,...RHEA-AIpositive
11/07/22 8:00 AMNasdaq : SESN earningsSesen Bio Reports Third Quarter 2022 Financial Results and Business UpdateOn September 21, 2022, Sesen Bio announced that it had entered into a definitive merger agreement with Carisma Therapeutics. The combined company will focus on the development of Carisma’ s chimeric antigen receptor macrophage therapies, which are believed to be the only therapies of their kind with demonstrated proof of mechanism and safety data in...RHEA-AIneutral